Display Settings:


Send to:

Choose Destination
Rev Med Interne. 2009 May;30(5):411-5. doi: 10.1016/j.revmed.2008.12.015. Epub 2009 Feb 23.

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].

[Article in French]

Author information

  • 1Service d'oncologie médicale, hôpital Saint-Antoine, 75571 Paris cedex 12, France. christophe.tournigand@sat.aphp.fr


Colorectal cancer remains one of the major causes of cancer death. Recent identification of new molecular targets led to the development of novel agents directed against growth factor receptors or key factors of angiogenesis. Recent phase III trials demonstrated a significant clinical benefit with bevacizumab, a VEGF inhibitor, and with EGFR-inhibitors, namely cetuximab and panitumumab. In this article we review the diverse treatment options combining cytotoxic and targeted therapies available for patients with metastatic colorectal cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk